CA3030659A1 - Multimeric gitr binding molecules and uses thereof - Google Patents

Multimeric gitr binding molecules and uses thereof Download PDF

Info

Publication number
CA3030659A1
CA3030659A1 CA3030659A CA3030659A CA3030659A1 CA 3030659 A1 CA3030659 A1 CA 3030659A1 CA 3030659 A CA3030659 A CA 3030659A CA 3030659 A CA3030659 A CA 3030659A CA 3030659 A1 CA3030659 A1 CA 3030659A1
Authority
CA
Canada
Prior art keywords
seq
binding molecule
gitr
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3030659A
Other languages
English (en)
French (fr)
Inventor
Beatrice Tien-Yi WANG
Bruce Alan Keyt
Ramesh Baliga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of CA3030659A1 publication Critical patent/CA3030659A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3030659A 2016-07-20 2017-07-20 Multimeric gitr binding molecules and uses thereof Abandoned CA3030659A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364762P 2016-07-20 2016-07-20
US62/364,762 2016-07-20
PCT/US2017/043166 WO2018017889A1 (en) 2016-07-20 2017-07-20 Multimeric gitr binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CA3030659A1 true CA3030659A1 (en) 2018-01-25

Family

ID=60992910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030659A Abandoned CA3030659A1 (en) 2016-07-20 2017-07-20 Multimeric gitr binding molecules and uses thereof

Country Status (9)

Country Link
US (2) US20190330360A1 (enExample)
EP (1) EP3487299A4 (enExample)
JP (1) JP2019528683A (enExample)
CN (1) CN109561681A (enExample)
AU (1) AU2017300647A1 (enExample)
CA (1) CA3030659A1 (enExample)
IL (1) IL263800A (enExample)
MX (1) MX2019000799A (enExample)
WO (1) WO2018017889A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
SG11201707144VA (en) 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
EP3758752A4 (en) 2018-03-01 2021-12-15 IGM Biosciences Inc. IGM-FC AND J-CHAIN MUTATIONS AFFECTING IGM SERUM HALF-LIFE
JP2022505663A (ja) * 2018-10-23 2022-01-14 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子
AU2020329301A1 (en) 2019-08-15 2022-02-17 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
BR112022021392A2 (pt) * 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
WO2022109023A1 (en) * 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN113151186B (zh) * 2021-02-04 2022-02-18 上海交通大学 抗人cd271的单克隆抗体及用途
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
DK3148579T3 (da) * 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
AU2015271709B2 (en) * 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
JP7179464B2 (ja) * 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
US11639389B2 (en) * 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain

Also Published As

Publication number Publication date
AU2017300647A1 (en) 2019-02-07
US20220177595A1 (en) 2022-06-09
CN109561681A (zh) 2019-04-02
WO2018017889A1 (en) 2018-01-25
IL263800A (en) 2019-02-28
EP3487299A4 (en) 2020-03-11
JP2019528683A (ja) 2019-10-17
US20190330360A1 (en) 2019-10-31
EP3487299A1 (en) 2019-05-29
MX2019000799A (es) 2019-06-03

Similar Documents

Publication Publication Date Title
US20220177595A1 (en) Multimeric gitr binding molecules and uses thereof
US20220169751A1 (en) Multimeric ox40 binding molecules and uses thereof
US20210388098A1 (en) Multimeric cd137/4-1bb binding molecules and uses thereof
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
US20220106399A1 (en) Multimeric cd40 binding molecules and uses thereof
US20220106398A1 (en) Anti-gitr antigen-binding domains and uses thereof
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231017